Search

Your search keyword '"Mantry, Parvez"' showing total 345 results
Start Over Author "Mantry, Parvez"
345 results on '"Mantry, Parvez"'

2. Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma

Author

Singal, Amit G, Rich, Nicole E, Mehta, Neil, Branch, Andrea D, Pillai, Anjana, Hoteit, Maarouf, Volk, Michael, Odewole, Mobolaji, Scaglione, Steven, Guy, Jennifer, Said, Adnan, Feld, Jordan J, John, Binu V, Frenette, Catherine, Mantry, Parvez, Rangnekar, Amol S, Oloruntoba, Omobonike, Leise, Michael, Jou, Janice H, Bhamidimarri, Kalyan Ram, Kulik, Laura, Ioannou, George N, Huang, Annsa, Tran, Tram, Samant, Hrishikesh, Dhanasekaran, Renumathy, Duarte-Rojo, Andres, Salgia, Reena, Eswaran, Sheila, Jalal, Prasun, Flores, Avegail, Satapathy, Sanjaya K, Kagan, Sofia, Gopal, Purva, Wong, Robert, Parikh, Neehar D, and Murphy, Caitlin C

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Liver Disease, Chronic Liver Disease and Cirrhosis, Digestive Diseases, Cancer, Emerging Infectious Diseases, Clinical Research, Hepatitis, Rare Diseases, Prevention, Infectious Diseases, Liver Cancer, Hepatitis - C, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Infection, Good Health and Well Being, Aged, Antiviral Agents, Carcinoma, Hepatocellular, Female, Hepatitis C, Humans, Liver Neoplasms, Male, Middle Aged, North America, Protective Factors, Retrospective Studies, Risk Assessment, Risk Factors, Time Factors, Treatment Outcome, HCC, Survival, Neurosciences, Paediatrics and Reproductive Medicine, Gastroenterology & Hepatology, Clinical sciences, Nutrition and dietetics
Abstract

Background & aimsThere is controversy regarding the benefits of direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) infection for patients with a history of hepatocellular carcinoma (HCC). We performed a multicenter cohort study to compare overall survival between patients with HCV infection treated with DAAs and patients who did not receive DAA treatment for their HCV infection after complete response to prior HCC therapy.MethodsWe conducted a retrospective cohort study of patients with HCV-related HCC who achieved a complete response to resection, local ablation, transarterial chemo- or radioembolization, or radiation therapy, from January 2013 through December 2017 at 31 health care systems throughout the United States and Canada. We used Cox proportional hazards regression to determine the association between receipt of DAA therapy, modeled as a time-varying covariate, and all-cause mortality, accounting for informative censoring and confounding using inverse probability weighting.ResultsOf 797 patients with HCV-related HCC, 383 (48.1%) received DAA therapy and 414 (51.9%) did not receive treatment for their HCV infection after complete response to prior HCC therapy. Among DAA-treated patients, 43 deaths occurred during 941 person-years of follow-up, compared with 103 deaths during 526.6 person-years of follow-up among patients who did not receive DAA therapy (crude rate ratio, 0.23; 95% confidence interval [CI], 0.16-0.33). In inverse probability-weighted analyses, DAA therapy was associated with a significant reduction in risk of death (hazard ratio, 0.54; 95% CI, 0.33-0.90). This association differed by sustained virologic response to DAA therapy; risk of death was reduced in patients with sustained virologic response to DAA therapy (hazard ratio, 0.29; 95% CI, 0.18-0.47), but not in patients without a sustained virologic response (hazard ratio, 1.13; 95% CI, 0.55-2.33).ConclusionsIn an analysis of nearly 800 patients with complete response to HCC treatment, DAA therapy was associated with a significant reduction in risk of death.

Published
2019

3. WED-211 Combination of Liverfast (LF) and Liver Stiffness Measurement (LSM) using fibroscan uutperforms FIB-4 and LSM, for the identification of MASLD advanced fibrosis (AF) in patients with type 2 diabetes (T2D)

Author

Dupuy, Julie, primary, Delamarre, Adèle, additional, Hermanbessiere, Paul, additional, Quiambao, Ronald, additional, Mantry, Parvez, additional, Alam, Imtiaz, additional, Munteanu, Mona, additional, and de Ledinghen, Victor, additional

Published
2024
Full Text
View/download PDF

4. LBO-005 Intervention with oral LPCN 1148 improves sarcopenia and hepatic encephalopathy (HE) in patients with cirrhosis: a 52-week phase 2 randomized clinical trial

Author

Bruno, Benjamin, primary, Weavil, Josh, additional, Ogle, Jonathan, additional, Chidambaram, Nachaippan, additional, Carey, Elizabeth, additional, Danford, Christopher, additional, Fricker, Zachary, additional, Galati, Joseph, additional, Lee, William M., additional, Mantry, Parvez, additional, Shetty, Kirti, additional, DelConte, Anthony, additional, Patel, Mahesh, additional, Sanyal, Arun J., additional, and Lai, Jennifer, additional

Published
2024
Full Text
View/download PDF

5. WED-294 The use of the FibroScan-AST score and AST to pre-identify metabolic dysfunction-associated steatohepatitis patients with active fibrogenesis in a Phase 1b open-label clinical trial

Author

Noureddin, Mazen, primary, Lawitz, Eric, additional, Alkhouri, Naim, additional, Kayali, Zeid, additional, Rudraraju, Madhavi, additional, Mena, Edward, additional, Loomba, Rohit, additional, Hassanein, Tarek, additional, Mantry, Parvez, additional, Siddiqui, Mohammad, additional, Lucas, Kathryn Jean, additional, Reiss, Garry, additional, Aneiros, Oni, additional, Farno, Dawn, additional, Differding, Shawna, additional, Marshall, Debbie, additional, Biracree, Jaime, additional, Devadas, Bruno, additional, Reddy, Praveena, additional, Patel, Chetna, additional, Tsau, Jennifer, additional, Chen, Michael, additional, Mendoza, Michelle, additional, Butler, Scott, additional, Oakley, Holly, additional, Lichtenberger, Wendi, additional, Hambridge, Shannon, additional, Thakker, Paresh, additional, Wennbo, Haakan, additional, Nagy, Peter, additional, and Derdak, Zoltan, additional

Published
2024
Full Text
View/download PDF

6. Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study

Author

Singal, Amit G, Rich, Nicole E, Mehta, Neil, Branch, Andrea, Pillai, Anjana, Hoteit, Maarouf, Volk, Michael, Odewole, Mobolaji, Scaglione, Steven, Guy, Jennifer, Said, Adnan, Feld, Jordan J, John, Binu V, Frenette, Catherine, Mantry, Parvez, Rangnekar, Amol S, Oloruntoba, Omobonike, Leise, Michael, Jou, Janice H, Bhamidimarri, Kalyan Ram, Kulik, Laura, Tran, Tram, Samant, Hrishikesh, Dhanasekaran, Renumathy, Duarte-Rojo, Andres, Salgia, Reena, Eswaran, Sheila, Jalal, Prasun, Flores, Avegail, Satapathy, Sanjaya K, Wong, Robert, Huang, Annsa, Misra, Suresh, Schwartz, Myron, Mitrani, Robert, Nakka, Sasank, Noureddine, Wassim, Ho, Chanda, Konjeti, Venkata R, Dao, Alexander, Nelson, Kevin, Delarosa, Kelly, Rahim, Usman, Mavuram, Meher, Xie, Jesse J, Murphy, Caitlin C, and Parikh, Neehar D

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Liver Disease, Emerging Infectious Diseases, Digestive Diseases, Rare Diseases, Hepatitis - C, Hepatitis, Chronic Liver Disease and Cirrhosis, Clinical Research, Liver Cancer, Cancer, Infectious Diseases, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Good Health and Well Being, Aged, Antiviral Agents, Canada, Carcinoma, Hepatocellular, Female, Hepatitis C, Chronic, Humans, Liver Neoplasms, Male, Middle Aged, Neoplasm Recurrence, Local, Retrospective Studies, Sustained Virologic Response, Time Factors, United States, Hepatitis C Virus, Recurrence, Direct-Acting Antiviral, Neurosciences, Paediatrics and Reproductive Medicine, Gastroenterology & Hepatology, Clinical sciences, Nutrition and dietetics
Abstract

Background & aimsThere is controversy over the effects of direct-acting antiviral (DAA) therapies for hepatitis C virus (HCV) infection on hepatocellular carcinoma (HCC) recurrence and tumor aggressiveness. We compared HCC recurrence patterns between DAA-treated and untreated HCV-infected patients who had achieved a complete response to HCC treatment in a North American cohort.MethodsWe conducted a retrospective cohort study of patients with HCV-related HCC with a complete response to resection, local ablation, transarterial chemo- or radioembolization, or radiation therapy from January 2013 through December 2017 at 31 health systems throughout the United States and Canada. Cox regression was used to examine the association between DAA therapy and time to recurrence after a complete response, with DAA therapy analyzed as a time-varying exposure. We also estimated the association between DAA therapy and risk of early HCC recurrence (defined as 365 days after complete response).ResultsOf 793 patients with HCV-associated HCC, 304 (38.3%) received DAA therapy and 489 (61.7%) were untreated. HCC recurred in 128 DAA-treated patients (42.1%; early recurrence in 52 patients) and 288 untreated patients (58.9%; early recurrence in 227 patients). DAA therapy was not associated with HCC recurrence (hazard ratio 0.90, 95% confidence interval 0.70-1.16) or early HCC recurrence (hazard ratio 0.96, 95% confidence interval 0.70-1.34) after we adjusted for study site, age, sex, Child-Pugh score, α-fetoprotein level, tumor burden, and HCC treatment modality. In DAA-treated and untreated patients, most recurrences were within the Milan criteria (74.2% vs 78.8%; P = .23). A larger proportion of DAA-treated than untreated patients received potentially curative HCC therapy for recurrent HCC (32.0% vs 24.6%) and achieved a complete or partial response (45.3% vs 41.0%) but this did not achieve statistical significance.ConclusionIn a large cohort of North American patients with complete response to HCC treatment, DAA therapy was not associated with increased overall or early HCC recurrence. HCC recurrence patterns, including treatment response, were similar in DAA-treated and untreated patients.

Published
2019

7. Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib

Author

Jayakumar, Saumya, Middleton, Michael S, Lawitz, Eric J, Mantry, Parvez S, Caldwell, Stephen H, Arnold, Hays, Diehl, Anna Mae, Ghalib, Reem, Elkhashab, Magdy, Abdelmalek, Manal F, Kowdley, Kris V, Djedjos, C Stephen, Xu, Ren, Han, Ling, Subramanian, G Mani, Myers, Robert P, Goodman, Zachary D, Afdhal, Nezam H, Charlton, Michael R, Sirlin, Claude B, and Loomba, Rohit

Subjects
Digestive Diseases, Hepatitis, Substance Misuse, Clinical Research, Chronic Liver Disease and Cirrhosis, Liver Disease, Biomedical Imaging, 4.2 Evaluation of markers and technologies, 4.1 Discovery and preclinical testing of markers and technologies, Detection, screening and diagnosis, Oral and gastrointestinal, Good Health and Well Being, Adolescent, Adult, Aged, Benzamides, Biopsy, Disease Progression, Dose-Response Relationship, Drug, Elasticity Imaging Techniques, Female, Humans, Imidazoles, Injections, Subcutaneous, Liver, Magnetic Resonance Imaging, Male, Middle Aged, Non-alcoholic Fatty Liver Disease, Pyridines, ROC Curve, Reproducibility of Results, Treatment Outcome, Young Adult, Non-alcoholic fatty liver disease, Non-alcoholic steatohepatitis, Hepatic steatosis, Non-invasive tests, Liver biopsy, Clinical Sciences, Public Health and Health Services, Gastroenterology & Hepatology
Abstract

Background & aimsNon-invasive tools for monitoring treatment response and disease progression in non-alcoholic steatohepatitis (NASH) are needed. Our objective was to evaluate the utility of magnetic resonance (MR)-based hepatic imaging measures for the assessment of liver histology in patients with NASH.MethodsWe analyzed data from patients with NASH and stage 2 or 3 fibrosis enrolled in a phase II study of selonsertib. Pre- and post-treatment assessments included centrally read MR elastography (MRE)-estimated liver stiffness, MR imaging-estimated proton density fat fraction (MRI-PDFF), and liver biopsies evaluated according to the NASH Clinical Research Network classification and the non-alcoholic fatty liver disease activity score (NAS).ResultsAmong 54 patients with MRE and biopsies at baseline and week 24, 18 (33%) had fibrosis improvement (≥1-stage reduction) after undergoing 24 weeks of treatment with the study drug. The area under the receiver operating characteristic curve (AUROC) of MRE-stiffness to predict fibrosis improvement was 0.62 (95% CI 0.46-0.78) and the optimal threshold was a ≥0% relative reduction. At this threshold, MRE had 67% sensitivity, 64% specificity, 48% positive predictive value, 79% negative predictive value. Among 65 patients with MRI-PDFF and biopsies at baseline and week 24, a ≥1-grade reduction in steatosis was observed in 18 (28%). The AUROC of MRI-PDFF to predict steatosis response was 0.70 (95% CI 0.57-0.83) and the optimal threshold was a ≥0% relative reduction. At this threshold, MRI-PDFF had 89% sensitivity and 47% specificity, 39% positive predictive value, and 92% negative predictive value.ConclusionsThese preliminary data support the further evaluation of MRE-stiffness and MRI-PDFF for the longitudinal assessment of histologic response in patients with NASH.Lay summaryLiver biopsy is a potentially painful and risky method to assess damage to the liver due to non-alcoholic steatohepatitis (NASH). We analyzed data from a clinical trial to determine if 2 methods of magnetic resonance imaging - 1 to measure liver fat and 1 to measure liver fibrosis (scarring) - could potentially replace liver biopsy in evaluating NASH-related liver injury. Both imaging methods were correlated with biopsy in showing the effects of NASH on the liver.

Published
2019

8. Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naïve patients: Findings from two randomized trials.

Author

Tam, Edward, Luetkemeyer, Anne F, Mantry, Parvez S, Satapathy, Sanjaya K, Ghali, Peter, Kang, Minhee, Haubrich, Richard, Shen, Xianlin, Ni, Liyun, Camus, Gregory, Copans, Amanda, Rossaro, Lorenzo, Guyer, Bill, Brown, Robert S, and RESCUE and ACTG A5348 study investigators

Subjects
RESCUE and ACTG A5348 study investigators, Humans, Hepacivirus, Hepatitis C, Chronic, HIV Infections, Liver Cirrhosis, Headache, Fatigue, Benzimidazoles, Fluorenes, Ribavirin, Uridine Monophosphate, Antiviral Agents, Pregnancy, Adult, Aged, Middle Aged, Female, Male, Coinfection, Sofosbuvir, Sustained Virologic Response, HCV, HIV, ledipasvir, sofosbuvir, treatment-experienced, Gastroenterology & Hepatology, Clinical Sciences
Abstract

Background & aimsWe report data from two similarly designed studies that evaluated the efficacy, safety, and optimal duration of ledipasvir/sofosbuvir (LDV/SOF) ± ribavirin (RBV) for retreatment of chronic hepatitis C virus (HCV) in individuals who failed to achieve sustained virological response (SVR) with prior SOF-based, non-NS5A inhibitor-containing regimens.MethodsThe RESCUE study enrolled HCV mono-infected adults with genotype (GT) 1 or 4. Non-cirrhotic participants were randomized to 12 weeks of LDV/SOF or LDV/SOF + RBV. Compensated cirrhotic participants were randomized to LDV/SOF + RBV (12 weeks) or LDV/SOF (24 weeks). The AIDS Clinical Trials Group A5348 study randomized genotype 1 adults with HCV/HIV co-infection to LDV/SOF + RBV (12 weeks) or LDV/SOF (24 weeks). Both studies used SVR at 12 weeks post-treatment (SVR12) as the primary endpoint.ResultsIn the RESCUE study, 82 participants were randomized and treated, and all completed treatment. Overall, SVR12 was 88% (72/82); 81-100% in non-cirrhotic participants treated with LDV/SOF or LDV/SOF + RBV for 12 weeks and 80-92% in cirrhotic participants treated with LDV/SOF + RBV for 12 weeks or LDV/SOF for 24 weeks. Adverse events (AEs), mostly mild-to-moderate in severity, were experienced by 78% of participants, with headache and fatigue most frequently reported. One serious AE, not related to treatment, was observed. No premature discontinuations of study drug, or deaths occurred. In the A5348 study, seven participants were randomized (cirrhotic n = 1; GT1a n = 5) and all attained SVR12, with no serious AEs or premature discontinuations.ConclusionsIn this SOF-experienced, NS5A inhibitor-naïve population, which included participants with cirrhosis or HCV/HIV co-infection, high SVR12 rates were achieved.

Published
2018

9. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial

Author

Loomba, Rohit, Lawitz, Eric, Mantry, Parvez S, Jayakumar, Saumya, Caldwell, Stephen H, Arnold, Hays, Diehl, Anna Mae, Djedjos, C Stephen, Han, Ling, Myers, Robert P, Subramanian, G Mani, McHutchison, John G, Goodman, Zachary D, Afdhal, Nezam H, Charlton, Michael R, and Investigators, for the GS‐US‐384‐1497

Subjects
Clinical Trials and Supportive Activities, Digestive Diseases, Chronic Liver Disease and Cirrhosis, Liver Disease, Hepatitis, Clinical Research, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Oral and gastrointestinal, Antibodies, Monoclonal, Humanized, Benzamides, Elasticity Imaging Techniques, Female, Humans, Imidazoles, Liver Cirrhosis, MAP Kinase Kinase Kinase 5, Male, Middle Aged, Non-alcoholic Fatty Liver Disease, Protein Kinase Inhibitors, Pyridines, GS-US-384-1497 Investigators, Medical Biochemistry and Metabolomics, Clinical Sciences, Immunology, Gastroenterology & Hepatology
Abstract

Inhibition of apoptosis signal-regulating kinase 1, a serine/threonine kinase, leads to improvement in inflammation and fibrosis in animal models of nonalcoholic steatohepatitis. We evaluated the safety and efficacy of selonsertib, a selective inhibitor of apoptosis signal-regulating kinase 1, alone or in combination with simtuzumab, in patients with nonalcoholic steatohepatitis and stage 2 or 3 liver fibrosis. In this multicenter phase 2 trial, 72 patients were randomized to receive 24 weeks of open-label treatment with either 6 or 18 mg of selonsertib orally once daily with or without once-weekly injections of 125 mg of simtuzumab or simtuzumab alone. The effect of treatment was assessed by paired pretreatment and posttreatment liver biopsies, magnetic resonance elastography, magnetic resonance imaging-estimated proton density fat fraction, quantitative collagen content, and noninvasive markers of liver injury. Due to the lack of effect of simtuzumab on histology or selonsertib pharmacokinetics, selonsertib groups with and without simtuzumab were pooled. After 24 weeks of treatment, the proportion of patients with a one or more stage reduction in fibrosis in the 18-mg selonsertib group was 13 of 30 (43%; 95% confidence interval, 26-63); in the 6-mg selonsertib group, 8 of 27 (30%; 95% confidence interval, 14-50); and in the simtuzumab-alone group, 2 of 10 (20%; 95% confidence interval, 3-56). Improvement in fibrosis was associated with reductions in liver stiffness on magnetic resonance elastography, collagen content and lobular inflammation on liver biopsy, as well as improvements in serum biomarkers of apoptosis and necrosis. There were no significant differences in adverse events between the treatment groups. Conclusion: These findings suggest that selonsertib may reduce liver fibrosis in patients with nonalcoholic steatohepatitis and stage 2-3 fibrosis. (Hepatology 2018;67:549-559).

Published
2018

10. Liver function and portal‐systemic shunting quantified by the oral cholate challenge test and risk for large oesophageal varices.

Author

Hassanein, Tarek, Keaveny, Andrew P., Mantry, Parvez, Smith, Alastair D., McRae, Michael P., Kittelson, John, Helmke, Steve, Everson, Gregory T., Bambha, Kiran, Fuchs, Michael, Gilroy, Richard K., Reddy, K. Rajender, Shiffman, Mitchell L., Rahimi, Robert S., Hellstern, Paul A., Hill, John M., Kayali, Zeid, Denham, Doug, Qureshi, Kamran, and Smith, Brian

Subjects
ESOPHAGEAL varices, ORAL drug administration, LIVER diseases, LIVER function tests, GENERATING functions
Abstract

Summary: Background: The quantitative HepQuant SHUNT test of liver function and physiology generates a disease severity index (DSI) that correlates with risk for clinical complications, such as large oesophageal varices (LEVs). A derivative test, HepQuant DuO, generates an equivalent DSI and simplifies testing by requiring only oral administration of the test solution and two blood samples at 20 and 60 min. Aims: Since the DSIs measured from DuO and SHUNT are equivalent, we compared the diagnostic performance for large oesophageal varices (LEVs) between the DSIs measured from DuO and SHUNT tests. Methods: This study combined the data from two prospectively conducted US studies: HALT‐C and SHUNT‐V. A total of 455 subjects underwent both the SHUNT test and esophagogastroduodenoscopy (EGD). Results: DSI scores correlated with the probability of LEVs (p < 0.001) and demonstrated a stepwise increase from healthy lean controls without liver disease to subjects with chronic liver disease and no, small or large varices. Furthermore, a cutoff of DSI ≤ 18.3 from DuO had a sensitivity of 0.98 (missing only one case) and, if applied to the endoscopy (EGD) decision, would have prevented 188 EGDs (41.3%). The AUROC for DSI from DuO did not differ from that of the reference SHUNT test method (0.82 versus 0.81, p = 0.3500). Conclusions: DSI from HepQuant DuO links liver function and physiology to the risk of LEVs across a wide spectrum of patient characteristics, disease aetiologies and liver disease severity. DuO is minimally invasive, easy to administer, quantitative and may aid the decision to avoid or perform EGD for LEVs. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

Author

Gadano, Adrian, Martins, Marcelo, Angus, Peter, Bate, John, Danta, Mark, George, Jacob, Hodge, Alexander, Kontorinis, Nickolas, Roberts, Stuart, Sanagapalli, Santosh, Skoien, Richard, Thompson, Alexander, Zekry, Amany, Stauber, Rudolf, Trauner, Michael, Moreno, Christophe, Reynaert, Hendrik, Verbeke, Len, Silva, Mario Reis Alvares da, Parise, Edison, Oliveira, Claudia Pinto Marques Souza de, Araujo, Roberta Chaves, Martinelli, Ana de Lourdes Candolo, Borman, Meredith, Chandok, Natasha, Elkhashab, Magdy, Fraser, Hughie, Kaita, Kelly, Ma, Mang, Marotta, Paul, Ramji, Alnoor, Tam, Edward, Yoshida, Eric, Swain, Mark, Sebastiani, Giada, Petrunia, Denis, Abergel, Armando, Anty, Rodolphe, Bourlière, Marc, Boursier, Jérôme, Bureau, Christophe, Castera, Laurent, Habersetzer, François, Hézode, Christophe, Ledinghen, Victor De, Leroy, Vincent, Loustaud-Ratti, Véronique, Mathurin, Philippe, Pol, Stanislas, Zoulim, Fabien, Hinrichsen, Holger, Ingiliz, Patrick, Lammert, Frank, Manns, Michael, Schattenberg, Jörn, Schiefke, Ingolf, Trautwein, Christian, Zeuzem, Stefan, Hui, Aric, Li, King-Kong, Wong, Vincent, Acharya, Subrat, Chowdhury, Abhijit, Duseja, Ajay, Kapoor, Dharmesh, Mukewar, Shrikant, Sarin, Shiv, Shah, Samir, Shalimar, Sood, Ajit, Tantry, BV, Ben-Ari, Ziv, Katchman, Helena, Safadi, Rifaat, Veitsman, Ella, Zuckerman, Eli, Brunetto, Maurizia, Lampertico, Pietro, Mangia, Alessandra, Akahane, Takemi, Akuta, Norio, Eguchi, Yuichiro, Fujiyama, Shigetoshi, Genda, Takuya, Hiasa, Yoichi, Ido, Akio, Ikeda, Fusao, Ikegami, Tadashi, Imajo, Kento, Itoh, Yoshito, Iwasa, Motoh, Karino, Yoshiyasu, Kato, Naoya, Kawaguchi, Takumi, Kawanaka, Miwa, Kido, Masahiro, Kobayashi, Tomoo, Kurosaki, Masayuki, Matsuzaki, Yasushi, Mita, Eiji, Mizukoshi, Eishiro, Nakahara, Takashi, Nomura, Hideyuki, Notsumata, Kazuo, Okanoue, Takeshi, Saito, Satoshi, Sakugawa, Hiroshi, Suzuki, Yoshiyuki, Takaguchi, Koichi, Takaki, Akinobu, Takashima, Tomoyuki, Tanaka, Saiyu, Tsuji, Keiji, Ueno, Yoshiyuki, Umemura, Takeji, Uto, Hirofumi, Yamashita, Nobuyuki, Yanase, Mikio, Yatsuhashi, Hiroshi, Yoneda, Masashi, Chan, Wah Kheong, Tan, Soek Siam, Garza, Laura Cisneros, Ladron De Guevara Cetina, Alma, Angeles, Rocio Guadalupe Vargas, Silva, Francisca Martinez, Van Erpecum, Karel, Orr, David, Jabłkowski, Maciej, Jaroszewicz, Jerzy, Ramos, Jose, Ahmed, Taufique, Ang, Tiing, Dan, Yock young, Goh, Boon Bee, Kaliyaperumal, Kalaiyarasi, Yip, Cherng Hann, Baik, Soon Koo, Jang, Byoung Kuk, Jun, Dae Won, Kim, Won, Kim, Hyung Joon, Kim, Ji Hoon, Lee, Kwan Sik, Lee, Chun Kyon, Lim, Young-Suk, Park, Jun Yong, Tak, Won Young, Augustin, Salvador, Perez, Salvador Benlloch, Caballeria, Juan, Luis, Jose, Panero, Calleja, Rodríguez, Jose Carrión, Garcia, Javier Crespo, Samaniego, Javier Garcia, Gibert, Pere Ginès, Prieto, Martin, Gomez, Manuel Romero, Turnes, Juan, Dufour, Jean-Francois, Moriggia, Alberto, Sheen, I-Shyan, Kao, Jia-Horng, Cheng, Pin-Nan, Huang, Jee-Fu, Yang, Sheng-Shun, Su, Wei-Wen, Chen, Chi-Yi, Chien, Rong-Nan, Lo, Gin-Ho, Chu, Chi-Jen, Wang, Horng-Yuan, Hu, Jui-Ting, Huang, Yi Wen, Agarwal, Kosh, Allison, Michael, Anstee, Quentin, Austin, Andrew, Fowell, Andrew, Ch'ng, Chin Lye, Manousou, Pinelopi, Newsome, Philip, Ryder, Stephen, Shankar, Arun, Abdelmalek, Manal, Abrams, Gary, Aguilar, Humberto, Alam, Imtiaz, Alba, Laura, Alkhouri, Naim, Allen, Alina, Aqel, Bashar, Balart, Luis, Barritt, A. Sidney, IV, Behari, Jaideep, Bennett, Michael, Bernstein, David, Bhandari, Bal Raj, Bonacini, Maurizio, Borg, Brian, Brown, Kimberly, Bzowej, Natalie, Caldwell, Stephen, Chami, Tawfik, Coates, Allan, Cueli, Adolfo, Davis, Mitchell, deLemos, Andrew, Desai, Archita, Dunn, Winston, Ferreira, Nelson, Fine, Michael, Firpi-Morell, Roberto, Freedland, Curtis, Freilich, Bradley, Fuchs, Michael, Galambos, Michael, Gallegos-Orozco, Juan, Galler, Greg, Ghali, Maged, Ghalib, Reem, Gill, Satinder, Gillis, Marcum, Gilroy, Richard, Gordon, Stuart, Gunn, Nadege, Halegoua-DeMarzio, Dina, Hassan, Mohamed, Hassanein, Tarek, Herring, Robert, Jr., Hong, John, Huang, Jonathan, Kabler, Heidi, Kayali, Zeid, Knapple, Whitfield, Kolli, Geetha, Kowdley, Kris, Krause, Richard, Lawitz, Eric, Lidofsky, Steven, Lim, Joseph, Lipkis, Donald, Loomba, Rohit, Mahgoub, Amar, Malespin, Miguel, Manch, Richard, Mannis, Steven, Manos, Paul, McDonald, Thomas, McKenzie, Mark, Mena, Edward, Merriman, Raphael, Moehlen, Martin William, Montgomery, Richard, Murphy, Robert, Natarajan, Yamini, Neff, Guy, Noureddin, Mazen, Ortiz-Lasanta, Grisell, Pagadala, Mangesh, Patel, Keyur, Patton, Heather, Peyton, Adam, Pimstone, Neville, Poulos, John, Pound, David, Pyrsopoulos, Nikolaos, Rafiq, Nila, Ravendhran, Natarajan, Ravinuthala, Ravi, Reddy, K. Rajendar, Reindollar, Robert, Reynolds, Justin, Rinella, Mary, Rizvi, Syed, Rockey, Don, Rodriguez-Perez, Federico, Ruane, Peter, Rubin, Raymond, Ryan, Michael, Saeian, Kia, Sanyal, Arun, Sarkar, Souvik, Scanga, Andrew, Schiff, Eugene, Schmidt, Warren, Schneider, Jeffrey, Sepe, Thomas, Shah, Dhiren, Shaikh, Obaid, Shankar, Uday, Sheikh, Aasim, Sheikh, Muhammad, Sherman, Kenneth, Shiffman, Mitchell, Siddique, Asma, Smith, Matthew, Suarez, Rosa, Talal, Andrew, Te, Helen, Tekola, Bezawit, Tetri, Brent, Thuluvath, Paul, Toro, Doris, Torres, Dawn, Trinh, Huy, Trotter, James, Vento, Angel, Vierling, John, Vuppalanchi, Raj, Waters, Michael, Weisberg, Ilan, Wieland, Amanda, Williams, Alonzo, Younes, Ziad, Adams, Leon, Harding, Damian, Hodge, Alex, Kontorinis, Nick, Strasser, Simone, Thompson, Alex, Horsmans, Yves, Steenkiste, Christophe Van, Bailey, Robert, Giard, Jeanne-Marie, Montano-Loza, Aldo, Puglia, Marco, Tsoi, Keith, Larrey, Dominique, Nguyen-Khac, Eric, Ratziu, Vlad, Spengler, Ulrich, Wiegand, Johannes, Hui, Aric Josun, Acharya, Subrat Kumar, Sarin, Shiv Kumar, Tantry, Vishwanath, Braun, Marius, Hazzan, Rawi, Lurie, Yoav, Colombo, Massimo, Fujii, Hideki, Hashimoto, Etsuko, Kato, Masaki, Ogawa, Koji, Takehara, Tetsuo, Tokushige, Katsutoshi, Garza, Laura Esthela Cisneros, Ladrón De Guevara, Alma Laura, Schultz, Michael, Janczewska, Ewa, Toro, Doris H., Jeong, Sook-Hyang, Kim, Yoon Jun, Lee, Jin-Woo, Ang, Tiing Leong, Bee, George Goh Boon, Benlloch, Salvador, Caballería, Juan, Calleja, José Luis, Rodríguez, Jose A. Carrión, Crespo, Javier, Diago, Moises, Fernandez-Rodriguez, Conrado, García-Samaniego, Javier, Ginès, Pere, Romero, Manuel, Dufour, Jean-François, Alazawi, William, Ch'ng, Chin-Lye, Forton, Daniel, Priest, Matthew, Sheridan, David, Ankoma-Sey, Victor, Balakrishnan, Maya, Bambha, Kiran, Barritt, A. Sidney, Bhandari, Bal, Brandman, Danielle, Chang, Charissa, Corey, Kathleen, Feldman, Michael, Gholam, Pierre, Goff, John, Marzio, Dina Halegoua-De, Harrison, Stephen, Hellstern, Paul, Jr., Herring, Robert, Iyer, Rajalakshmi, Jakiche, Antoine, Kohli, Anita, Krok, Karen, Kugelmas, Marcelo, Kumar, Sonal, Lai, Michelle, Mahmoud, Mitchell, Mantry, Parvez, Marsano, Luis, Nguyen, Tuan, Park, James, Patton, Heather M., Pockros, Paul, Reddy, Rajender, Rodriguez, Miguel, Sarles, Harry, Satapathy, Sanjaya, Sedghi, Shahriar, Shah, Nikunj, Sheikh, Muhammad Yasin, Sigal, Samuel, Stanca, Carmen, Steinbook, Michael, Szabo, Gyongyi, Terrault, Norah, Tong, Myron, Victor, David, Zervos, Xaralambos, Harrison, Stephen A., Wong, Vincent Wai-Sun, Caldwell, Stephen H., Shiffman, Mitchell L., Camargo, Marianne, Li, Georgia, Kersey, Kathryn, Jia, Catherine, Zhu, Yanni, Djedjos, C. Stephen, Subramanian, G. Mani, Myers, Robert P., Anstee, Quentin M., Romero-Gomez, Manuel, Goodman, Zachary, Lawitz, Eric J., and Younossi, Zobair

Published
2020
Full Text
View/download PDF

12. Provider Attitudes and Practice Patterns for Direct-Acting Antiviral Therapy for Patients With Hepatocellular Carcinoma

Author

Rich, Nicole E., Yang, Ju Dong, Perumalswami, Ponni V., Alkhouri, Naim, Jackson, Whitney, Parikh, Neehar D., Mehta, Neil, Salgia, Reena, Duarte-Rojo, Andres, Kulik, Laura, Rakoski, Mina, Said, Adnan, Oloruntoba, Omobonike, Ioannou, George N., Hoteit, Maarouf A., Moon, Andrew M., Rangnekar, Amol S., Eswaran, Sheila L., Zheng, Elizabeth, Jou, Janice H., Hanje, James, Pillai, Anjana, Hernaez, Ruben, Wong, Robert, Scaglione, Steven, Samant, Hrishikesh, Kapuria, Devika, Chandna, Shaun, Rosenblatt, Russell, Ajmera, Veeral, Frenette, Catherine T., Satapathy, Sanjaya K., Mantry, Parvez, Jalal, Prasun, John, Binu V., Fix, Oren K., Leise, Michael, Lindenmeyer, Christina C., Flores, Avegail, Patel, Nayan, Jiang, Z. Gordon, Latt, Nyan, Dhanasekaran, Renumathy, Odewole, Mobolaji, Kagan, Sofia, Marrero, Jorge A., and Singal, Amit G.

Published
2020
Full Text
View/download PDF

13. First-308: Phase III study of tinengotinib versus physician's choice in patients with FGFR-altered, chemotherapy- and FGFR inhibitor–refractory/relapsed cholangiocarcinoma.

Author

Javle, Milind M., primary, Rimassa, Lorenza, additional, Goyal, Lipika, additional, Mahipal, Amit, additional, Fountzilas, Christos, additional, Liao, Chih-Yi, additional, Pelster, Meredith, additional, Mantry, Parvez, additional, Bridgewater, John A, additional, Hollebecque, Antoine, additional, Vandamme, Timon, additional, Wyrwicz, Lucjan, additional, Peng, Peng, additional, Sun, Caixia, additional, Hennessy, Katie, additional, Wang, Hui, additional, Fu, Ximei, additional, Wu, Frank, additional, Fan, Jean, additional, and Oh, Do-Youn, additional

Published
2024
Full Text
View/download PDF

14. FOENIX-CCA4: A phase 2 study of futibatinib 20 mg and 16 mg in patients with advanced cholangiocarcinoma (CCA) and fibroblast growth factor receptor 2 (FGFR2) fusions/rearrangements.

Author

Macarulla, Teresa, primary, Mizuno, Takashi, additional, Brandi, Giovanni, additional, Li, Jin, additional, Chen, Ming-Huang, additional, Kang, Jung Hun, additional, Abdalla, Kathia Cristina, additional, Wysocki, Piotr Jan, additional, Couto, Nuno, additional, Anderson, Bailey, additional, Elsayed, Hamdy, additional, and Mantry, Parvez, additional

Published
2024
Full Text
View/download PDF

15. Efficacy and safety results of FGFR1-3 inhibitor, tinengotinib, as monotherapy in patients with advanced, metastatic cholangiocarcinoma: Results from phase II clinical trial.

Author

Javle, Milind M., primary, Mahipal, Amit, additional, Kankeu Fonkoua, Lionel Aurelien, additional, Fountzilas, Christos, additional, Li, Daneng, additional, Pelster, Meredith, additional, Liao, Chih-Yi, additional, Richards, Donald A., additional, Deming, Dustin A., additional, Younes, Mohamad Ahmad, additional, Mantry, Parvez, additional, Cohn, Allen Lee, additional, Kingsley, Ed, additional, Fan, Jean, additional, Peng, Peng, additional, Sun, Caixia, additional, Wang, Hui, additional, Hennessy, Katie, additional, Shan, Yujun, additional, and Wu, Frank, additional

Published
2024
Full Text
View/download PDF

21. Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis

Author

Asselah, Tarik, Kowdley, Kris V., Zadeikis, Neddie, Wang, Stanley, Hassanein, Tarek, Horsmans, Yves, Colombo, Massimo, Calinas, Filipe, Aguilar, Humberto, de Ledinghen, Victor, Mantry, Parvez S., Hezode, Christophe, Marinho, Rui Tato, Agarwal, Kosh, Nevens, Frederik, Elkhashab, Magdy, Kort, Jens, Liu, Ran, Ng, Teresa I., Krishnan, Preethi, Lin, Chih-Wei, and Mensa, Federico J.

Published
2018
Full Text
View/download PDF

23. Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials

Author

Jensen, Donald M., Asselah, Tarik, Dieterich, Douglas, Foster, Graham R., Sulkowski, Mark S., Zeuzem, Stefan, Mantry, Parvez, Yoshida, Eric M., Moreno, Christophe, Ouzan, Denis, Wright, Mark, Morano, Luis E., Buynak, Robert, Bourlière, Marc, Hassanein, Tarek, Nishiguchi, Shuhei, Kao, Jia-Horng, Omata, Masao, Paik, Seung W., Wong, David K., Tam, Edward, Kaita, Kelly, Feinman, S. Victor, Stern, Jerry O., Scherer, Joseph, Quinson, Anne-Marie, Voss, Florian, Gallivan, John-Paul, Böcher, Wulf O., and Ferenci, Peter

Published
2016
Full Text
View/download PDF

24. Editorial: Reading the cholate—A new gateway to portal hypertension and oesophageal varices: Authors' reply.

Author

Hassanein, Tarek, Keaveny, Andrew P., Mantry, Parvez, Smith, Alastair D., McRae, Michael P., Kittelson, John, Helmke, Steve, and Everson, Gregory T.

Subjects
ESOPHAGEAL varices, PORTAL hypertension, AUTHORS
Abstract

LINKED CONTENT: This article is linked to Hassanein et al papers. To view these articles, visit https://doi.org/10.1111/apt.18054 and https://doi.org/10.1111/apt.18113 [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

28. Extracorporeal cellular therapy (ELAD) in severe alcoholic hepatitis: A multinational, prospective, controlled, randomized trial

Author

Thompson, Julie, Jones, Natasha, Al‐Khafaji, Ali, Malik, Shahid, Reich, David, Munoz, Santiago, MacNicholas, Ross, Hassanein, Tarek, Teperman, Lewis, Stein, Lance, Duarte‐Rojo, Andrés, Malik, Raza, Adhami, Talal, Asrani, Sumeet, Shah, Nikunj, Gaglio, Paul, Duddempudi, Anupama, Borg, Brian, Jalan, Rajiv, Brown, Robert, Patton, Heather, Satoskar, Rohit, Rossi, Simona, Parikh, Amay, ElSharkawy, Ahmed, Mantry, Parvez, Sher, Linda, Wolf, David, Hart, Marquis, Landis, Charles, Wigg, Alan, Habib, Shahid, McCaughan, Geoffrey, Colquhoun, Steven, Henry, Alyssa, Bedard, Patricia, Landeen, Lee, Millis, Michael, Ashley, Robert, Frank, William, Henry, Andrew, Stange, Jan, and Subramanian, Ram

Published
2018
Full Text
View/download PDF

29. Safety and efficacy of the farnesoid X receptor (FXR) agonist cilofexor in a proof-of-concept study in patients with compensated cirrhosis due to primary sclerosing cholangitis (PSC)

Author

Levy, Cynthia, primary, Caldwell, Stephen, additional, Mantry, Parvez, additional, Luketic, Velimir, additional, Landis, Charles, additional, Huang, Jonathan, additional, Mena, Edward, additional, Maheshwari, Rahul, additional, Rank, Kevin, additional, Xu, Jun, additional, Lu, Xiangyu, additional, Lu, Xiaomin, additional, Chung, Chuhan, additional, Myers, Robert, additional, and Kowdley, Kris, additional

Published
2022
Full Text
View/download PDF

39. Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy

Author

Rockey, Don C., Vierling, John M., Mantry, Parvez, Ghabril, Marwan, Brown, Robert S., Jr., Alexeeva, Olga, Zupanets, Igor A., Grinevich, Vladimir, Baranovsky, Andrey, Dudar, Larysa, Fadieienko, Galyna, Kharchenko, Nataliya, Klarytsʼka, Iryna, Morozov, Vyacheslav, Grewal, Priya, McCashland, Timothy, Reddy, Gautham K., Reddy, Rajender K., Syplyviy, Vasyl, Bass, Nathan M., Dickinson, Klara, Norris, Catherine, Coakley, Dion, Mokhtarani, Masoud, and Scharschmidt, Bruce F.

Published
2014
Full Text
View/download PDF

42. Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis

Author

Frenette, Catherine, primary, Kayali, Zeid, additional, Mena, Edward, additional, Mantry, Parvez S., additional, Lucas, Kathryn J., additional, Neff, Guy, additional, Rodriguez, Miguel, additional, Thuluvath, Paul J., additional, Weinberg, Ethan, additional, Bhandari, Bal R., additional, Robinson, James, additional, Wedick, Nicole, additional, Chan, Jean L., additional, Hagerty, David T., additional, Kowdley, Kris V., additional, Corey, Kathleen, additional, Bernstein, David, additional, Noureddin, Mazen, additional, Kemmer, Nyingi, additional, DeLemos, Andrew, additional, Pyrsopoulos, Nikolaos, additional, Lee, William, additional, Ghabril, Marwan, additional, Scanga, Andrew, additional, McKenzie, Mark, additional, Lawitz, Eric, additional, Figueroa-Diaz, Viviana, additional, Simonetto, Douglas, additional, Frederick, Richard, additional, Brown, Kimberly, additional, Therapondos, George, additional, Sheikh, Aasim, additional, Brandman, Danielle, additional, Stein, Lance, additional, Ankoma-Sey, Victor, additional, Bhamidimarri, Kalyan, additional, Landis, Charles, additional, Fortune, Brett, additional, Vargas, Hugo, additional, Abdelmalek, Manal, additional, Freilich, Bradley, additional, Rockey, Don, additional, Vierling, John, additional, Tatum, Harvey, additional, Curry, Michael, additional, Shiffman, Mitchell, additional, Bambha, Kiran, additional, Ghalib, Reem, additional, Stratton, Amy, additional, Anwar, Nadeem, additional, Caldwell, Stephen, additional, Koteish, Ayman, additional, Siddiqui, Mohammad, additional, Saab, Sammy, additional, Shah, Nikunj, additional, Kohli, Anita, additional, Rinella, Mary, additional, Sarkar, Souvik, additional, Torres, Dawn, additional, Verna, Elizabeth, additional, Ravendhran, Ravi, additional, Reynolds, Justin, additional, Thomason, Ray, additional, Kim, Ray, additional, Membreno, Fernando, additional, Jakab, Sofia, additional, Gonzalez, Stevan, additional, Keaveny, Andrew, additional, Pan, Jen-Jung, additional, Gill, Satinder, additional, Huang, Jonathan, additional, Strobel, James, additional, Wieland, Amanda, additional, Morelli, Giuseppe, additional, Amankonah, Thomas, additional, Roytman, Marina, additional, Schmidt, Warren, additional, Abrams, Gary, additional, and Patel, Bhaktasharan, additional

Published
2021
Full Text
View/download PDF

44. Screening for Nonalcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the United States Is Cost-effective: A Comprehensive Cost-Utility Analysis

Author

Noureddin, Mazen, primary, Jones, Calum, additional, Alkhouri, Naim, additional, Gomez, Eduardo Vilar, additional, Dieterich, Douglas T., additional, Rinella, Mary E., additional, Therapondos, George, additional, Girgrah, Nigel, additional, Mantry, Parvez S., additional, Sussman, Norman L., additional, Figueroa Diaz, Viviana, additional, and Fuchs, Michael, additional

Published
2020
Full Text
View/download PDF

47. Featured Cover.

Author

Hassanein, Tarek, Keaveny, Andrew P., Mantry, Parvez, Smith, Alastair D., McRae, Michael P., Kittelson, John, Helmke, Steve, and Everson, Gregory T.

Abstract

The cover image is based on the Original Article Liver function and portal‐systemic shunting quantified by the oral cholate challenge test and risk for large oesophageal varices by Tarek Hassanein et al., https://doi.org/10.1111/apt.18054.By Tarek Hassanein; Andrew P. Keaveny; Parvez Mantry; Alastair D. Smith; Michael P. McRae; John Kittelson; Steve Helmke and Gregory T. EversonReported by Author; Author; Author; Author; Author; Author; Author; Author [Extracted from the article]

Published
2024
Full Text
View/download PDF

50. Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study

Author

Newsome, Philip N., primary, Palmer, Melissa, additional, Freilich, Bradley, additional, Sheikh, Muhammad Y., additional, Sheikh, Aasim, additional, Sarles, Harry, additional, Herring, Robert, additional, Mantry, Parvez, additional, Kayali, Zeid, additional, Hassanein, Tarek, additional, Lee, Hak-Myung, additional, and Aithal, Guruprasad P., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results